Scorpion toxin peptide BMK86-P1 achieves mutation-reversible inhibition of KCNA2 at the cost of reduced…

Abstract

The discovery of distinctive function-phenotype relationships in monogenetic channelopathies has turned out to be critical for the development of precision medicine approaches. However, the best prediction of clinical phenotypes depends on neuronal function, where existing models lack tools to isolate currents of individual voltage-gated potassium channel subunits and differentiate variant effects in complex systems. Ideally, one should be able to overexpress subunit variants with an additional mutation that confers resistance against the tool to isolate the variant effect. Therefore, we solid-phase synthesized the KV1.2 specific scorpion toxin peptide BMK86-P1 and oxidized it with modest efficacy. In mammalian cells this BMK86-P1 selectively inhibited KV1.2 homomers, but not heteromers with KV1.1. Critically, the KCNA2 p.Val381Tyr mutation, which reverses BMK86-P1's selective inhibition of KV1.2, also altered the activation of KV1.2 homomers to resemble those of KV1.1. In addition, BMK86-P1 in murine neurons did not alter passive membrane properties, single action potential properties, or action potential firing. Surprisingly, it induced only minimal changes in spontaneous excitatory postsynaptic currents. In summary, this KV1.2 subunit selective toxin peptide asserts its effects primarily on homomeric channels, while only weakly inhibiting KV1.2-heteromeric channels and consequently preventing any meaningful impact on neuronal function. This highlights the limits of peptide synthesis together with the need for testing specific compounds on complex systems.

Reversible inhibition of medial septum interneurons abolishes initial acquisition of new place-reward associations and reveals a progressive reduction in dependence on medial septal function
Z. Alizadeh, J. Ferbinteanu, M. Eckert +3
bioRxiv25 Sep 2026PreprintCC BYFull textNeurosciencebioRxiv
Suspected Microvascular Occlusion Syndrome Following Scorpion Envenomation: A Pediatric Case Report
Rana Sadat Saleh, Fateme Jadidi, Reyhane Mohsenifard +2
Case Reports in Pediatrics2 Nov 2026Peer-reviewedCC BY 4.0Full textGenetics & genomicsPMC
Gas gill respiration enhances underwater copulation in a water scorpion
Hyoseul Hyun, Nikolai J. Tatarnic, Chang S. Han
iScience13 Oct 2026Peer-reviewedCC BY 4.0Full textZoology & animal behaviourCell PressCrossrefEurope PMC
Oldest North American orthostern scorpion from the Carboniferous (Pennsylvanian: Bashkirian) Pottsville Formation of Alabama, USA
Gen A. Conway, Russell D. C. Bicknell, Bruno A. Buzatto +1
Die Naturwissenschaften27 Oct 2026Peer-reviewedCC BY 4.0Full textEcologyPMC
Characterization of a Ten-Cysteine Peptide from Scorpion That Inhibits Classical Complement Activation via C4/C4b
Xudong Luo, Wen Zhu, Yuwei Wang +9
Biomolecules1 Oct 2026Peer-reviewedCC BY 4.0Full textImmunologyCrossrefEurope PMC

Cite

BibTeX RIS

BibTeX

@misc{brand2026scorpion,
  title = {{Scorpion toxin peptide BMK86-P1 achieves mutation-reversible inhibition of KCNA2 at the cost of reduced efficacy in heteromers and murine neurons}},
  author = {E. M. M. Brand and L. Over and H. Kalbacher and R. Lambert and S. Iavarone and H. Lyu and U. B. S. Hedrich and P. Müller-Wöhrstein},
  howpublished = {bioRxiv},
  year = {2026},
  month = aug,
  doi = {10.64898/2026.08.28.747831},
  url = {https://www.biorxiv.org/content/10.64898/2026.08.28.747831v1},
  note = {CC BY},
}

RIS

TY  - UNPB
TI  - Scorpion toxin peptide BMK86-P1 achieves mutation-reversible inhibition of KCNA2 at the cost of reduced efficacy in heteromers and murine neurons
AU  - E. M. M. Brand
AU  - L. Over
AU  - H. Kalbacher
AU  - R. Lambert
AU  - S. Iavarone
AU  - H. Lyu
AU  - U. B. S. Hedrich
AU  - P. Müller-Wöhrstein
PY  - 2026
DA  - 2026/08/28
PB  - bioRxiv
DO  - 10.64898/2026.08.28.747831
UR  - https://www.biorxiv.org/content/10.64898/2026.08.28.747831v1
AB  - The discovery of distinctive function-phenotype relationships in monogenetic channelopathies has turned out to be critical for the development of precision medicine approaches. However, the best prediction of clinical phenotypes depends on neuronal function, where existing models lack tools to isolate currents of individual voltage-gated potassium channel subunits and differentiate variant effects in complex systems. Ideally, one should be able to overexpress subunit variants with an additional mutation that confers resistance against the tool to isolate the variant effect. Therefore, we solid-phase synthesized the KV1.2 specific scorpion toxin peptide BMK86-P1 and oxidized it with modest efficacy. In mammalian cells this BMK86-P1 selectively inhibited KV1.2 homomers, but not heteromers with KV1.1. Critically, the KCNA2 p.Val381Tyr mutation, which reverses BMK86-P1's selective inhibition of KV1.2, also altered the activation of KV1.2 homomers to resemble those of KV1.1. In addition, BMK86-P1 in murine neurons did not alter passive membrane properties, single action potential properties, or action potential firing. Surprisingly, it induced only minimal changes in spontaneous excitatory postsynaptic currents. In summary, this KV1.2 subunit selective toxin peptide asserts its effects primarily on homomeric channels, while only weakly inhibiting KV1.2-heteromeric channels and consequently preventing any meaningful impact on neuronal function. This highlights the limits of peptide synthesis together with the need for testing specific compounds on complex systems.
ER  -

Abstract

Related

Cite